Merck: Keytruda gets double-approval in Japan
(CercleFinance.com) - US pharmaceutical giant Merck announced on Monday that the Japanese drug agency had given its approval for two new uses of its immunotherapy Keytruda.
The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has authorised the marketing of this antibody called "anti-PD1" in the treatment of squamous cell carcinoma of the esophagus.
The health authority has also approved a new dosage of the anti-cancer agent, which can now be administered intravenously at 400 mg every six weeks for all indications in adults.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has authorised the marketing of this antibody called "anti-PD1" in the treatment of squamous cell carcinoma of the esophagus.
The health authority has also approved a new dosage of the anti-cancer agent, which can now be administered intravenously at 400 mg every six weeks for all indications in adults.
Copyright (c) 2020 CercleFinance.com. All rights reserved.